Wearable patch doubles arrhythmia detection after unexplained fainting
The ASPIRED randomized trial analyzed 2,233 adults with unexplained syncope across 45 UK hospitals and found that fitting a 14-day waterproof adhesive chest patch at or soon after the emergency visit led to arrhythmia detection in 22 percent versus 9 percent with standard care, and shortened median time to diagnosis from 55 to 22 days. Earlier detection increased earlier treatment, including more anti-arrhythmic prescriptions (10.8% versus 7.3%) and pacemaker implants (6.8% versus 4.6%). The trial missed its primary endpoint on fainting recurrence, and a lower one-year mortality with monitoring was a secondary finding requiring confirmation.
Immediate 14-day chest patch doubled arrhythmia detection after unexplained syncope.
Context
A large randomized trial presented at a cardiology congress and published in a major journal drove this report. It tested immediate 14-day patch monitoring against usual care for unexplained fainting. Next steps could include guideline…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked